Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
2011
The prognosis of
multiple myelomapatients has significantly improved since the introduction of the novel agents
thalidomide,
bortezomiband
lenalidomide. We report the data of a medical need programme with
lenalidomideplus
dexamethasone, conducted in Belgium between August 2007 and March 2008, and including 98 relapsed refractory
multiple myelomapatients. In addition to chemotherapy and steroids, all patients had received prior treatment with
bortezomib, and 84% of them had been exposed to
thalidomide. In 52 patients response data could be retrieved by
post-hoc analysis. A partial remission or better was achieved in 52% (49% partial and 3% complete response) of patients, despite a median of 5 previous anti-myeloma treatment lines. Responses were rapid while the majority of patients received
lenalidomidewith once weekly (also called low-dose)
dexamethasone. Treatment with
lenalidomideplus
dexamethasonedid prolong overall survival by nearly half a year in this population with end-stage myeloma. Overall response and quality of response were independent of previous response to
thalidomideand
bortezomib, although the time to progression tended to be shorter in
thalidomide- and
bortezomib-refractory patients. It can be concluded that
lenalidomideplus
dexamethasoneis an effective and safe treatment regimen in highly refractory
multiple myelomapatients, and that these responses are irrespective of previous exposure or sensitivity to
thalidomideand
bortezomib.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
4
Citations
NaN
KQI